



Integra LifeSciences to Present At the UBS Global Life Sciences Conference and Natixis Bleichroeder's Hidden Gems Conference

PLAINSBORO, N.J., Sep 17, 2007 (PrimeNewswire via COMTEX News Network) --

Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it is scheduled to present at the UBS Global Life Sciences Conference at the Grand Hyatt New York on Wednesday, September 26, 2007, and at Natixis Bleichroeder's Hidden Gems Conference on Monday, October 8, 2007 at The Carlton on Madison, both in New York City.

The UBS presentation will be delivered by Stuart Essig, Integra's Chief Executive Officer. A live webcast of this presentation can be accessed through a link provided on the home page of the Investor Relations section of Integra's website at <http://www.integra-LS.com>. Additionally, a replay of this webcast will be available for two weeks following the live broadcast.

John B. Henneman, III, Integra's Executive Vice President, Chief Administrative Officer, and Acting Chief Financial Officer will deliver the presentation at Natixis Bleichroeder's conference. This presentation will not be webcast.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (<http://www.Integra-LS.com>).

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2006 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-G

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation

John B. Henneman, III, Executive Vice President, Chief
Administrative Officer, Acting Chief Financial Officer
(609) 936-2481

jhenneman@Integra-LS.com

John Bostjancic, Vice President, Corporate Development
and Investor Relations

(609) 936-2239

jbostjancic@integra-LS.com

(C) Copyright 2007 PrimeNewswire, Inc. All rights reserved.

News Provided by COMTEX